Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for Dianthus Therapeutics (DNTH) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Dianthus Therapeutics' Amortizatization of Intangibles fell 128.15% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 11126.58%. This contributed to the annual value of $6.0 million for FY2024, which is 32290.93% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Amortizatization of Intangibles stood at $2.3 million for Q3 2025, which was down 128.15% from $1.1 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Amortizatization of Intangibles high stood at $2.7 million for Q4 2024, and its period low was -$115000.0 during Q1 2022.
  • For the 4-year period, Dianthus Therapeutics' Amortizatization of Intangibles averaged around $890333.3, with its median value being $432000.0 (2022).
  • As far as peak fluctuations go, Dianthus Therapeutics' Amortizatization of Intangibles tumbled by 2361.11% in 2023, and later skyrocketed by 60939.39% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Amortizatization of Intangibles (Quarter) stood at $402000.0 in 2022, then surged by 31.09% to $527000.0 in 2023, then soared by 419.35% to $2.7 million in 2024, then fell by 15.56% to $2.3 million in 2025.
  • Its Amortizatization of Intangibles stands at $2.3 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.9 million for Q1 2025.